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Abstract
Background: Patients with severe asthma have increased airway remodelling and elevated numbers of circulating
fibrocytes with enhanced myofibroblastic differentiation capacity, despite being treated with high doses of
corticosteroids, and long acting β2-adrenergic receptor (AR) agonists (LABAs). We determined the effect of
β2-AR agonists, alone or in combination with corticosteroids, on fibrocyte function.
Methods: Non-adherent non-T cells from peripheral blood mononuclear cells isolated from healthy subjects
and patients with non-severe or severe asthma were treated with the β2-AR agonist, salmeterol, in the presence or
absence of the corticosteroid dexamethasone. The number of fibrocytes (collagen I+/CD45+ cells) and differentiating
fibrocytes (α-smooth muscle actin+ cells), and the expression of CC chemokine receptor 7 and of β2-AR were
determined using flow cytometry. The role of cyclic adenosine monophosphate (cAMP) was elucidated using
the cAMP analogue 8-bromoadenosine 3′,5′-cyclic monophosphate (8-Br-cAMP) and the phosphodiesterase
type IV (PDE4) inhibitor, rolipram.
Results: Salmeterol reduced the proliferation, myofibroblastic differentiation and CCR7 expression of fibrocytes
from healthy subjects and non-severe asthma patients. Fibrocytes from severe asthma patients had a lower
baseline surface β2-AR expression and were relatively insensitive to salmeterol but not to 8-Br-cAMP or
rolipram. Dexamethasone increased β2-AR expression and enhanced the inhibitory effect of salmeterol on
severe asthma fibrocyte differentiation.
Conclusions: Fibrocytes from patients with severe asthma are relatively insensitive to the inhibitory effects
of salmeterol, an effect which is reversed by combination with corticosteroids.
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Background
Asthmatic inflammation is characterised by extensive
airway remodelling involving sub-epithelial fibrosis and
thickening of the airway smooth muscle (ASM) layer [1].
5–10% of asthmatic patients suffer from severe asthma,
which is difficult to control despite receiving high-dose
inhaled corticosteroids and long-acting β2-adrenoceptor
(β2-AR) agonists (LABA), leukotriene modifiers or theo-
phylline [2]. In severe asthmatic airways, there is more
prominent sub-epithelial fibrosis and ASM thickening
which contribute to airway obstruction [3].
Fibrocytes are bone marrow-derived progenitor cells that
express leukocytes markers, such as CD45, and mesenchy-
mal proteins, including collagen I [4]. Migration of fibrocytes
towards allergen-exposed airways and their subsequent dif-
ferentiation into α–smooth muscle actin (SMA)-expressing
myofibroblasts may contribute to increased ASM mass and
sub-epithelial fibrosis [5]. Fibrocyte accumulation has also
been observed in the airways of severe refractory asthmatic
patients [6]. The CC chemokine receptor 7 (CCR7)/CC
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chemokine ligand 19 axis is important in the migration of
fibrocytes from asthmatic patients with chronic airflow ob-
struction [7]. We have previously shown that severe asthma
patients have more circulating fibrocytes, with higher myofi-
broblastic differentiation potential and relative corticosteroid
insensitivity in vitro [8].
The use of LABAs in conjunction with inhaled cortico-
steroids results in further improvement of symptoms and
lung function [9]. β2-AR activation induces the production
of 3′,5′-cyclic adenosine monophosphate (cAMP) by ade-
nylyl cyclase leading to airway smooth muscle relaxation
[10]. β2-AR agonists also exert other effects on cellular
function such as inhibition of proliferation, α–SMA expres-
sion and collagen synthesis in pulmonary fibroblasts [11,
12]. Corticosteroid insensitivity in peripheral blood mono-
nuclear cells (PBMCs) from patients with severe asthma
has been associated with reduced glucocorticoid receptor
(GR) nuclear translocation and hyper-phosphorylation of
GR, effects that are reversed by β2-AR agonists [13].
We hypothesised that β2-AR activation has differential
effects on the function of fibrocytes from severe asthma
patients compared to healthy subjects and non-severe
asthma patients. We determined the effect of the β2-AR
agonist, salmeterol, in the presence or absence of the cor-
ticosteroid dexamethasone on the number, differentiation
potential, and CCR7 and β2-AR expression in fibrocytes
from patients with non-severe and severe asthma and
healthy subjects. The involvement of cAMP in the down-
stream signalling was investigated using the phospho-
diesterase (PDE) 4 inhibitor rolipram and the cAMP
analogue 8-bromoadenosine 3′,5′-cyclic monophosphate
(8-Br-cAMP) on fibrocytes in cultured non-adherent non-
T (NANT) cells from severe asthmatic subjects.
Methods
Subjects
Patients with severe and non-severe asthma and healthy
subjects were recruited as previously described [8],
according to the American Thoracic Society guidelines for
refractory asthma (Table 1) [14]. The study was approved
by the local ethics committee and informed consent was
obtained from each participant. Additional details on the
method are provided in the Additional file 1.
Isolation of NANT cells
NANT cells were isolated as previously described [8].
Briefly, PBMCs were isolated from peripheral blood
using Ficoll-Paque™ PLUS density gradient centrifuga-
tion (GE HealthCare, Uppsala, Sweden). Adherent cells
were depleted by adherence, and T cells in the non-
adherent fraction of PBMCs were removed using CD3+
MicroBeads according to the manufacturer’s instructions
(Miltenyi Biotec, California, USA). The NANT cells were
then incubated in Iscove’s Modified Dulbecco’s Medium
(IMDM; Sigma-Aldrich) supplemented with 30% FBS
(Sigma-Aldrich) and 1% BSA in a humidified incubator,
at 37∘C with 5% CO2, for 3 days in the presence or
absence of treatments. NANT cells were counted on a
haemocytometer after Trypan blue staining.
Analysis of fibrocytes by flow cytometry
Fibrocytes were identified in the NANT cell population, as
cells positive for collagen I and CD45 (Col I+/CD45+), by
flow cytometry [8]. NANT cells were fixed using 0.5% para-
formaldehyde, washed twice with phosphate buffered saline
(PBS) and incubated with an allophycocyanin (APC)-conju-
gated mouse anti-human CD45 antibody (BD Biosciences,
#555485, San Jose, California, USA). In some experiments
cells were also stained with a phycoerythrin (PE)–conju-
gated mouse anti-human CCR7 antibody (BD Biosciences,
#150503) 0.125 μg for 30 min. Cells were then permeabi-
lised using 1X BD FACS Permeabilising Solution 2 (BD
Biosciences, #347692) 120 μl for 15 min and then stained
using 0.015 μg of fluorescein isothiocyanate (FITC)-conju-
gated mouse anti-human collagen I antibody (Millipore
Corporation, #FCMAB412F, Temecula, California) for
Table 1 Clinical characteristics of study subjects
Healthy Non-severe Asthma Severe Asthma
Number 12 9 13
Age, years 39.8 ± 2.5 52.6 ± 4.2 54.4 ± 3.8*
Gender, Female/Male 6/6 7/2 11/2
Inhaled corticosteroid dose, μg BDP equivalent 0 150.0 ± 105.2 2000 ± 258.2**##
Atopy (n) 5 4 5
Receiving oral corticosteroids 0 0 4
Pre-bronchodilator FEV1 (L) 3.4 ± 0.2 2.2 ± 0.3 1.5 ± 0.2***
Pre-bronchodilator FEV1 of predicted value (%) 94.9 ± 2.5 82.3 ± 5.5 61.0 ± 5.5***
FEV1/FVC (%) 88.2 ± 2.3 69.5 ± 2.0 64.5 ± 3.1***
Data are expressed as mean ± SEM
BDP beclomethasone dipropionate, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
*p < 0.05, ***p < 0.001 compared to healthy subjects. ## p < 0.01 compared to patients with non-severe asthma
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30 min.. Differentiating fibrocytes were identified as α–
SMA-positive (α–SMA+) cells, by staining permeabilised
NANT cells with 0.125 μg of PE-conjugated mouse anti-
human α–SMA antibody (R&D Systems, #IC1420P Abing-
don, UK). Cells incubated with isotype-matched antibodies
were used as negative controls.
To evaluate the expression of β2-AR on the surface,
cells were incubated with 1 μg of unconjugated rabbit
IgG anti-human β2-AR (Abcam, #ab61778, Cambridge,
UK,) and 0.015 μg of anti-human CD45 antibody for
30 min, followed by a PE–conjugated goat IgG anti-
rabbit polyclonal secondary antibody (Abcam, #ab97070)
0.3 μg for 30 min, permeablised and then stained with
FITC-conjugated anti-human collagen I antibody 0.5 μg
for 30 min.
To evaluate the expression of β2-AR in the whole cell,
cells were incubated with anti-human CD45 antibody,
permeablised, then stained with 1 μg of unconjugated
rabbit IgG anti-human β2-AR and 0.5 μg of FITC-
conjugated anti-human collagen I antibody for 30 min,
followed by 0.5 μ of PE–conjugated goat IgG anti-rabbit
polyclonal secondary antibody g for 30 min.
Analysis of NANT cell apoptosis using Annexin V and
propidium iodide (PI) staining
NANT cell apoptosis was determined by Annexin V and
propidium iodide (PI) staining using the FITC Annexin
V/Dead cell apoptosis kit (Invitrogen, Paisley, UK) ac-
cording to the manufacturer’s instructions. Briefly, fol-
lowing treatment, NANT cells were washed in PBS,
incubated with FITC-conjugated annexin V and PI and
analysed by flow cytometry. Annexin V−/PI− were con-
sidered live cells, Annexin V+/PI− as early apoptotic and
annexin V+/PI+ as late apoptotic cells.
Statistical analysis
Data are presented as mean ± standard error of the mean
(SEM). Statistical analysis was carried out using the
GraphPad Prism v.5 software package (GraphPad Prism
Software Inc., California, USA). Intra-group comparisons
of more than two conditions were carried out using the
Friedman test followed by Dunn’s post-hoc test and pair-
wise comparisons using a paired t-test. Inter-group com-
parisons were carried out using the Mann-Whitney test.
p < 0.05 was considered as statistically significant.
Results
Effect of salmeterol on fibrocyte number, differentiation
and CCR7 expression
At the time of isolation from blood (day 0) the total
number of NANT cells were not significantly different
between groups, however there were higher percentages
of fibrocytes in severe asthma (51 ± 11 × 103; 15% ± 2.2)
compared to non-severe asthma (43 ± 5 × 103; 6.7% ± 1
and healthy subjects (15 ± 4.2 × 103; 4.1% ± 0.9). For ex-
periments, 1 × 106 NANT cells per well were seeded at
day 0. After three days in culture, there was a concomi-
tant increase in the percentage of fibrocytes within each
group (Additional file 2: Figure S3A), suggesting prolifer-
ation of fibrocytes in culture. In contrast to day 0, at day
3 there were no significant differences in the percentage
of fibrocytes across the groups. However, there was an
higher percentage of differentiated (α–SMA+) fibrocytes
in the severe asthma group compared to non-severe
asthma patients and healthy subjects (Additional file 2:
Figure S3B) confirming our previous observations [8].
As the vast majority of α–SMA+ cells also expressed the
fibrocyte markers Col I and CD45, we chose to identify
differentiating fibrocytes by single α–SMA staining
(Additional file 3: Figure S1).
Incubation with salmeterol (10−9 - 10−7 M) for 3 days
led to a decrease in the number of fibrocytes (Fig. 1a)
and differentiating fibrocytes (Fig. 1b) from healthy sub-
jects and non-severe asthma patients. Salmeterol did not
modulate the percentage of apoptotic NANT cells (Add-
itional file 4: Figure S2). As we have shown that fibro-
cytes proliferate in culture the reduction in fibrocyte
number by salmeterol is possibly a result of inhibition of
proliferation. In contrast, salmeterol did not modulate
the number of fibrocytes (Fig. 1a) and differentiating
fibrocytes (Fig. 1b) from patients with severe asthma.
We also show that there is an increase in the absolute
number of fibrocytes in culture at day 3 in all three
groups suggesting proliferation of fibrocytes in culture.
Pre-treatment with salmeterol inhibited this proliferation
in fibrocytes from healthy subjects and non-severe asth-
matics but the anti-proliferative effect of salmeterol was
not observed in severe asthma. The effect of salmeterol
on the absolute numbers of fibrocytes and differentiating
fibrocytes is shown in Additional file 2: Figure S3. Sal-
meterol also led to a decrease in the percentage of
CCR7-positive fibrocytes (Fig. 1c) and CCR7 MFI ratio
(Fig. 1d) in NANT cells from patients with non-severe
asthma but had no significant effect on those from
healthy subjects and patients with severe asthma.
The suppressive effect of salmeterol on the number of
fibrocytes and differentiating fibrocytes from healthy sub-
jects was prevented in the presence of the β2-AR-specific
antagonist ICI-118,551 (10−5 M; Additional file 5: Figure
S4), confirming that the effects of salmeterol are mediated
by β2-AR activation. The above findings suggest altered
β2-AR signalling in fibrocytes from severe asthma.
Effect of cAMP modulation on fibrocyte number and
differentiation
Increasing intracellular cAMP levels using the analogue 8-
Br-cAMP (10−4 – 10−3 M) led to a concentration-
dependent decrease in the number of fibrocytes (Fig. 2a)
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and differentiating fibrocytes (Fig. 2b) from both healthy
subjects and severe asthma patients. Also, the PDE4 inhibi-
tor rolipram (10−5 M), which inhibits PDE4-dependent
cAMP hydrolysis, alone and in combination with
salmeterol reduced fibrocyte number and differentiation
(Fig. 2c-d). The combination of salmeterol and rolipram
had a greater inhibitory effect on the number of fibro-
cytes and differentiated fibrocytes than either drug
alone, although these differences did not reach statis-
tical significance. Together these data suggest that the
a b
c d
Fig. 1 Effect of salmeterol on the number, differentiation and CCR7 expression of fibrocytes. NANT cells from healthy subjects (n = 8–9) and
patients with non-severe (n = 7) or severe asthma (n = 7–9) were treated with salmeterol (10−9- 10−7 M) for 3 days. Fibrocyte (Col I+/CD45+ cells;
a) and differentiating fibrocyte (α-SMA+ cells; b) number, and percentage (c) and median fluorescence intensity (MFI; d) of CCR7+ fibrocytes (Col I
+/CD45+/CCR7+ cells) were determined. Data points represent mean ± SEM. * p < 0.05 and ** p < 0.01 versus vehicle-treated cells for each group.
# p < 0.05 healthy versus severe asthma and & p < 0.05 non-severe asthma versus severe asthma
a b
c d
Fig. 2 Effect of cAMP modulation on fibrocyte number and differentiation. NANT cells from healthy subjects (n = 4) and severe asthma patients
(n = 4) were treated with 8-Br-cAMP (10−4- 10−3 M for 3 days (a-b). Alternatively, NANT cells from severe asthma patients were treated with rolipram
(10−5 M) in the presence or absence of salmeterol (10−9 M) for 3 days (c-d). The number of fibrocytes (Col I+/CD45+ cells; a and c) and differentiating
fibrocytes (α-SMA+ cells; b and d) were determined. Data points represent mean ± SEM. * p < 0.05 versus vehicle-treated cells for each group
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defect in β2-AR signalling in severe asthma fibrocytes
possibly lies upstream of cAMP production.
β2-AR expression in fibrocytes from healthy subjects and
severe asthma patients
The baseline, surface and whole cell, expression of β2-
AR was determined in fibrocytes, in the NANT cells of
healthy subjects and severe asthma patients at day 0 by
staining with an anti-β2-AR antibody before or after per-
meabilisation, respectively (Fig. 3a-d). Both the percent-
age of β2-AR-positive fibrocytes (Fig. 3e) and the β2-AR
MFI ratio (Fig. 3f ) were lower on the surface of circulat-
ing fibrocytes of patients with severe asthma compared
to healthy subjects, although whole cell β2-AR expres-
sion was not significantly different between the two
groups (Fig. 3g and h).
Incubation of NANT cells from healthy subjects with
salmeterol (10−8 M) for 3 days led to a reduction in the
percentage of fibrocytes positive for surface β2-AR
(Fig. 4a) and the surface β2-AR MFI ratio (Fig. 4b). Sal-
meterol had no effect on the percentage of fibrocytes
positive for whole cell β2-AR (Fig. 4c) but increased the
whole cell MFI ratio (Fig. 4d), in NANT cells from
healthy subjects. In contrast, salmeterol had no effect on
the percentage of β2-AR-positive fibrocytes (ColI
+/CD45
+/ β2-AR
+) or the MFI ratio, on the surface (Fig. 4e and
f) or in the whole cell (Fig. 4g and h), in NANT cells
from patients with severe asthma. These data suggest
loss of baseline surface β2-AR expression and attenuated
agonist-induced β2-AR down-regulation in fibrocytes
from severe asthma.
Effect of dexamethasone on salmeterol-induced effects
on fibrocyte function
To investigate whether the addition of a corticosteroid
modulates the effects of β2-AR activation on fibrocytes
of patients with severe asthma, NANT cells were incu-
bated with a submaximal dose of salmeterol (10−9 M) in
combination with dexamethasone (10−7 M). For all
groups there was an increase in the total the number
fibrocytes at day 3 as described above. Although dexa-
methasone or salmeterol alone had no effect on fibrocyte
number and differentiation, the number of differentiat-
ing fibrocytes (Fig. 5b), but not total fibrocytes (Fig. 5a),
was reduced by the combination of salmeterol and dexa-
methasone. Salmeterol and dexamethasone, individually
or in combination, had no effect on fibrocytes positive
for surface β2-AR (Fig. 5c). However, dexamethasone
alone led to a non-statistically-significant increase in the
β2-AR MFI ratio whilst the combination of salmeterol
and dexamethasone significantly augmented the β2-AR
MFI ratio (Fig. 5d). Thus, dexamethasone may potentiate
the effects of salmeterol on severe asthma fibrocytes by
increasing surface β2-AR density.
Discussion
We have demonstrated that β2-AR activation by salmeterol
leads to a reduction in the proliferation, myofibroblastic
differentiation and CCR7 expression in fibrocytes from
healthy subjects and patients with non-severe asthma. In
contrast, salmeterol had no effect on fibrocytes from severe
asthma patients indicating defective β2-AR signalling. In-
creasing intracellular cAMP levels, using the analogue 8-
Br-cAMP or inhibiting cAMP degradation using the PDE4
inhibitor, rolipram, led to reduction in the number and dif-
ferentiation of severe asthma fibrocytes indicating that the
defect possibly lies up-stream of cAMP production. Indeed,
we showed that fibrocytes from severe asthma patients
have reduced baseline surface β2-AR expression which was
not reduced further by salmeterol. Co-treatment with
dexamethasone increased surface β2-AR density and aug-
mented the inhibition of differentiation by salmeterol in
fibrocytes of patients with severe asthma.
The airways of patients with severe asthma patients
show increased airway remodelling despite receiving high
doses of inhaled and oral corticosteroids and LABAs [3].
Increased numbers of circulating fibrocytes, with in-
creased capacity to differentiate into myofibroblasts and
relative corticosteroid insensitivity may contribute to the
increased airway remodelling in severe asthma [8]. In this
study, we show that β2-AR activation by salmeterol can re-
duce the proliferation, differentiation and CCR7 expres-
sion of fibrocytes from healthy subjects and non-severe
asthmatic patients. These findings are consistent with
studies in fibroblasts showing inhibition of collagen syn-
thesis, expression of α–SMA and proliferation in response
to β2-AR agonists [11, 12, 15].
We also show that fibrocytes from severe asthma
are less sensitive to the inhibitory effects of salme-
terol suggesting that LABAs may be unable to reduce
fibrocyte numbers and myofibroblastic differentiation
in the airways of patients with severe asthma due to
defective β2-AR signalling. Activation of the β2-AR
leads to Gs-mediated activation of adenylyl cyclase
which catalyses the conversion of adenosine triphos-
phate (ATP) to cAMP leading to activation of PKA
and EPAC-dependent pathways [10]. Increasing intra-
cellular cAMP levels using 8-Br-cAMP mimicked the
inhibitory effect of β2-AR activation on the number
and differentiation of fibrocytes. These findings are in
line with studies showing reduction in proliferation,
myofibroblastic differentiation and chemotaxis of fi-
broblasts by cAMP [16–18]. Significantly, fibrocytes
from patients with severe asthma were also sensitive
to the inhibitory effects of the cAMP analogue, whilst
inhibiting cAMP hydrolysis using rolipram enhanced
the inhibitory effect of salmeterol on these cells.
These findings indicate that the signalling pathways
downstream to cAMP are intact in severe asthma
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fibrocytes and that the defect most likely lies at the
level of the β2-AR expression or activation.
We have demonstrated that severe asthmatic fibro-
cytes show reduced surface β2-AR expression, whilst
they have similar whole cell β2-AR expression levels,
compared to fibrocytes from healthy subjects. More-
over, salmeterol failed to reduce the surface β2-AR ex-
pression in fibrocytes from patients with severe asthma,
possibly due to the already low β2-AR surface density.
These findings indicate a possible defect in the mem-
brane localisation but not the overall expression of the
β2-AR in severe asthma fibrocytes. As this occurs in the
absence of salmeterol in vitro, it is possible that this is
due to chronic exposure to systemic LABAs or en-
dogenous circulating catecholamines and inflammatory
mediators in vivo [19, 20]. Prolonged β2-AR activation
triggers its uncoupling from adenylyl cyclase, internal-
isation of the uncoupled receptors, and increased
degradation of internalized receptors, leading to desen-
sitisation [21]. Under normal conditions β2-AR are sub-
sequently resensitised by recycling back to the cell
membrane to interact with agonists [22]. Defective β2-
AR resensitisation has been shown to cause reduced
baseline surface expression and attenuated agonist-
induced activation in ASM cells of subjects with fatal
asthma [23].
a b
c d
e f
g h
Fig. 3 Baseline β2-AR expression in fibrocytes from healthy subjects and patients with severe asthma. β2-AR expression in fibrocytes from untreated
NANT cells of healthy subjects (n = 11) and severe asthma patients (n = 6) was determined by staining with antibodies for collagen I (Col I), CD45 and
β2-AR (c-d), or their respective isotype controls (a-b) at day 0. Representative flow cytometry scatter plots from one experiment are shown. Surface
(e-f) and whole cell (g-h) β2-AR expression was determined as percentage of β2-AR+ fibrocytes (Col I+/CD45+/β2-AR+ cells; e, g) and median fluorescence
intensity (MFI) ratios (f, h). Horizontal lines represent the median of each group. * p< 0.05, ** p< 0.01
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The inhibitory effect of salmeterol on severe asthma
fibrocyte differentiation was restored by co-incubation
with the corticosteroid, dexamethasone. However, salme-
terol and dexamethasone did not modulate the total
number of fibrocytes from severe asthma patients in cul-
ture and this may be a result of the increased capacity of
fibrocytes from patients with severe asthma to survive,
as we have previously demonstrated [8]. Resistance to
the anti-proliferative effects of corticosteroids, due to re-
duced expression of CCAAT/enhancer binding protein α
(C/EBPα), was also reported in airway smooth muscle
cells from patients with asthma [24]. Corticosteroids
have been shown to potentiate β2-AR agonist effects by
increasing β2-AR density through up-regulation of tran-
scription [25]. In agreement with these findings, we
demonstrated up-regulation of the surface β2-AR MFI
ratio, indicating increased surface receptor density, in re-
sponse to dexamethasone and salmeterol in severe
asthma fibrocytes. Nonetheless, the superior effect of
salmeterol and dexamethasone combination may also be
a result of potentiation of glucocorticoid receptor (GR)
function by salmeterol, as β2-AR agonists are known to
induce GR nuclear translocation and modulate phos-
phorylation of GR, in PBMCs, lung fibroblasts and
a b
c d
e f
g h
Fig. 4 Effect of salmeterol on β2-AR expression in fibrocytes from healthy subjects and patients with severe asthma. NANT cells from healthy subjects
(a-d; n = 4) and severe asthma patients (e-h; n = 4) were treated with salmeterol (10−8 M) for 3 days. Surface (a-b and e-f) and whole cell (c-d and g-h)
β2-AR expression was determined as percentage of β2-AR
+ fibrocytes (Col I+/CD45+/β2-AR
+ cells; a, c, e, g) and median fluorescence intensity (MFI)
ratios (b, d, f, h). * p < 0.05 and ** p < 0.01
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airway smooth muscle cells [13, 26, 27]. A combination
of the corticosteroid, budesonide and the β2-AR agon-
ist, formoterol, has been shown to inhibit transforming
growth factor (TGF)–β1-induced collagen I synthesis,
whilst either drug alone had no effect [28]. Moreover, a
salmeterol and fluticasone propionate combination in-
hibits TGF–β1-induced α-SMA expression in lung
fibroblasts [11]. Thus, the combination of β2-AR ago-
nists and corticosteroids may be more potent in con-
trolling airway remodelling in severe asthma, than
either drug alone.
We showed that rolipram, a first generation selective
PDE4 inhibitor [29], enhanced the inhibitory effect of
salmeterol on the differentiation of fibrocytes from both
healthy subjects and severe asthma patients. Rolipram
has been shown to reverse endotoxin-induced airway
hyperresponsiveness and bronchoconstriction in vivo
[30], whilst PDE4 knockdown attenuates basic fibroblast
factor and interleukin-1β-induced proliferation, and
transforming growth factor-β-induced myofibroblastic
differentiation of fibroblasts [31]. Also, combination of
the β2-AR agonist, indacaterol, and the PDE4 inhibitor,
roflumilast, inhibits the expression of endothelin-1, con-
nective tissue growth factor and α-SMA, and the secre-
tion of fibronectin from normal human lung fibroblasts,
more strongly than with either drug alone [32]. Signifi-
cantly, rolipram was also shown to overcome β2-AR
desensitisation in ASM cells [33].
Conclusions
In this study we have demonstrated that fibrocytes from
patients with severe asthma show reduced surface β2-AR
expression and consequently insensitivity to the inhibi-
tory effects of β2-AR agonists. These findings, in
conjunction with our previous findings showing cortico-
steroid insensitivity in severe asthma fibrocytes, highlight
a possible mechanism underlining the accumulation of
fibrocytes in the circulation and lung tissue of severe
asthma patients [6, 8]. Moreover, we show that combin-
ation of β2-AR agonists with corticosteroids are more
effective in suppressing fibrocyte number and differenti-
ation than each drug alone highlighting the importance
of combination therapy in the treatment of remodelling
in severe asthma.
Additional files
Additional file 1: Supplementary Materials and Methods. (DOCX 19 kb)
Additional file 2: Figure S3. Number of fibrocytes and differentiating
fibrocytes in NANT cells after culture in the absence or presence of salmeterol.
The number of fibrocytes (% Col I+/CD45+; A) and differentiating fibrocytes
(% α-SMA+; B) within the NANT cell population, were determined in the NANT
cells from healthy subjects (n= 8–9) and patients with non-severe (n= 7) or
severe asthma (n = 7–9) at day 0 (0 d) or after 3 days (3 d) in the absence or
presence of salmeterol (10−9- 10−7 M). Data points represent mean ± SEM.
* p< 0.05 and ** p< 0.01 versus vehicle-treated cells for each group. ###
p< 0.001 versus healthy group and $$$ p < 0.001 versus non-severe asthma
group. (PDF 478 kb)
a b
c d
Fig. 5 Effect of salmeterol and dexamethasone combination on the number, differentiation and β2-AR expression of fibrocytes from severe
asthma patients. NANT cells from patients with severe asthma (n = 4–7) were treated with salmeterol (10−9 M) in the presence or absence of
dexamethasone (Dex; 10−7 M) for 3 days. The number of fibrocytes (Col I+/CD45+ cells; a) and differentiating fibrocytes (α-SMA+ cells; b), as well
as the percentage (Col I+/CD45+/β2-AR+; c) and median fluorescence intensity (MFI) ratio (d) of β2-AR–positive fibrocytes were determined. Bars
represent mean ± SEM. * p < 0.05
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Additional file 3: Figure S1. α–smooth muscle actin-positive cells also
express both collagen I and CD45. NANT cells from one healthy subject
were harvested after 3 days in culture and stained with antibodies for collagen
I (Col I), α- smooth muscle actin (SMA) and CD45 or their respective IgG
isotype controls. (A and C). The percentage of Col I+/α-SMA+ (B) and CD45
+/ α-SMA+ cells (D) was determined by flow cytometry. (PDF 112 kb)
Additional file 4: Figure S2. Effect of salmeterol on NANT cell apoptosis.
NANT cells from healthy subjects (n = 6) were treated with salmeterol
(10−8 M) for 3 days and the percentage of live, and early and late
apoptotic NANT cells was determined. Bars represent mean ± SEM.
(PDF 173 kb)
Additional file 5: Figure S4. Effect of ICI-118,551 on salmeterol-mediated
reduction in fibrocyte number and differentiation. NANT cells from healthy
subjects (n = 6) were treated with salmeterol (10−8 M) in the presence or
absence of ICI-118,551 (10−5 M) for 3 days. The number of fibrocytes (Col I
+/CD45+ cells; A) and differentiating fibrocytes (α-SMA+ cells; B) was
determined. Bars represent mean ± SEM.* p < 0.05 and ** p < 0.01.
(PDF 69 kb)
Abbreviations
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